

(19)



Europäisches Patentamt
European Patent Office
Office européen des brevets



(11) Publication number:

0 279 633 B1

(12)

EUROPEAN PATENT SPECIFICATION

- (43) Date of publication of patent specification: **07.04.93** (51) Int. Cl.⁵: **C07C 233/65**, C07C 233/67, C07C 323/00, C07D 233/61, A61K 31/165, A61K 31/415, C07C 233/81
- (21) Application number: **88301285.8**
- (22) Date of filing: **17.02.88**

The file contains technical information submitted after the application was filed and not included in this specification

(54) **Anticonvulsant agents.**(56) Priority: **18.02.87 US 16047**(42) Date of publication of application: **24.08.88 Bulletin 88/34**(45) Publication of the grant of the patent: **07.04.93 Bulletin 93/14**(64) Designated Contracting States:
AT BE CH DE ES FR GB GR IT LI LU NL SE

(69) References cited:
EP-A- 0 213 572
EP-A- 0 213 924
FR-A- 2 224 153
GB-A- 2 064 524

JOURNAL OF PHARMACEUTICAL SCIENCES, vol. 63, no. 1, 1974; C. RODRIGUEZ-SALAZAR, "New Compounds: Synthesis of p-Dialkylaminoalkoxybenzoxylidides as Possible Local Anesthetics"

JOURNAL OF MEDICINAL CHEMISTRY, vol. 28, no. 3, 1985, pages 295-298, D. M. STOUT

et al, "Synthesis and Antiarrhythmic and Parasympatholytic Properties of Substituted Phenols. 3. Modifications to the Linkage Region"

(73) Proprietor: **ELI LILLY AND COMPANY**
Lilly Corporate Center
Indianapolis Indiana 46285(US)

(72) Inventor: **Beedle, Edward Earl**
4119 Sherlock Drive
Indianapolis Indiana 46254(US)
Inventor: **Robertson, David Wayne**
720 Woodale Terrace No. 17
Greenwood Indiana 46142(US)

(24) Representative: **Tapping, Kenneth George et al**
Erl Wood Manor
Windsorham Surrey, GU20 6PH (GB)

Note: Within nine months from the publication of the mention of the grant of the European patent, any person may give notice to the European Patent Office of opposition to the European patent granted. Notice of opposition shall be filed in a written reasoned statement. It shall not be deemed to have been filed until the opposition fee has been paid (Art. 99(1) European patent convention).


Description

This invention relates to novel anti-convulsant agents, and to formulations and methods for treating or preventing seizures in epileptic patients.

The several anticonvulsant drugs marketed in the United States provide significant seizure relief for only 50-75% of epileptic patients. The therapeutic effects are sometimes accompanied by serious side effects such as sedation, ataxia, psychoses, suicidal depression, gastrointestinal disturbances, gingival hyperplasia, lymphadenopathies, megaloblastic anemias, hepatotoxicity, nephropathies, hirsutism, and fetal malformations. These side effects, which range in severity from mild sedation to death from aplastic anemia, are particularly troublesome since most of the marketed anticonvulsants have very low therapeutic ratios. For example, phenytoin, one of the most widely used anticonvulsants, controls seizures in man only when plasma levels reach 10 mcg/ml. Toxic effects such as nystagmus are seen at around 20 mcg/ml, ataxia is obvious at 30 mcg/ml, and lethargy is apparent at about 40 mcg/ml. See "The Pharmacological Basis of Therapeutics" (Gilman, Goodman, and Gilman, ed., 6th Ed., MacMillan Publishing Co., Inc., New York, New York (1980)), p. 455. In view of these facts, most epileptologists indicate that more selective and less toxic anticonvulsant drugs are needed.

Much to our surprise, we have found that compounds of the following Formula (I) with the unusual set of substituents at the 4 position of the benzoyl ring (for example, a mono- or disubstituted amino group) give excellent anti-convulsant activity while possessing minimal side effects.

According to the present invention there is provided a method for treating or preventing convulsions in mammals which comprises administering to said mammal a compound of the Formula (I):



wherein R_1 is hydroxy, C_1 - C_4 alkoxy, $-S(O)_p$ -(C_1 - C_4 alkyl) where p is 0 to 2, trifluoromethyl, C_1 - C_4 alkyl, aminomethyl, cyano, primary amido, 1-imidazolyl, or $-NR_3R_4$, where R_3 is hydrogen or C_1 - C_3 alkyl and R_4 is C_1 - C_3 alkyl, and

R_2 is methyl, methoxy, trifluoromethyl, hydroxymethyl, or chloro; or a pharmaceutically acceptable salt thereof.

According to a further aspect of the present invention, there are provided pharmaceutical formulations which comprise as an active ingredient a benzamide of formula (I), or a pharmaceutically-acceptable salt thereof, in association with one or more pharmaceutically acceptable carriers or excipients therefor.

The p -substituted benzamides of formula (I) wherein R_1 is $-S(O)_p$ -(C_1 - C_4 alkyl), where p is 0 to 2, trifluoromethyl, cyano, primary amido, 1-imidazolyl, or $-NR_3R_4$, where R_3 is hydrogen or C_1 - C_3 alkyl and R_4 is C_1 - C_3 alkyl, and

R_2 is methyl, methoxy, trifluoromethyl, hydroxymethyl, or chloro; or pharmaceutically acceptable salts thereof, are novel and are provided in a further aspect of the invention.

As used in the above formulas, the term " C_1 - C_4 alkyl" refers to straight and branched aliphatic residues of one to four carbon atoms such as methyl, ethyl, propyl, isopropyl, t -butyl, and the like, and includes within it the term " C_1 - C_3 alkyl".

The preferred compounds of this invention are those wherein R_2 is methyl and R_1 is $-NR_3R_4$. One class of methods, formulations and compounds which may be mentioned is that wherein R_1 is $-NR_3R_4$ wherein R_3 and R_4 are independently C_1 - C_3 alkyl and wherein R_3 is hydrogen when R_4 is methyl or ethyl and R_2 is methyl.


Particularly preferred compounds are 4-(dimethylamino)- N -(2,6-dimethylphenyl)benzamide, N -2,6-(dimethylphenyl)-4-(methoxy)benzamide, N -(2,6-dimethylphenyl)-4-(hydroxy)benzamide and N -(2,6-dimethylphenyl)-4-(methoxy)benzamide, and pharmaceutically acceptable salts thereof.

Structurally similar anticonvulsants are known from FR-A-2 224 153.

The pharmaceutically acceptable salts of this invention can be prepared by standard methods known in the art, for example, employing those acids of sufficient acidity to form acid addition salts of those compounds wherein R_1 is $-NR_3R_4$. These include salts derived from inorganic acids such as hydrochloric

acid, nitric acid, phosphoric acid, sulfuric acid, hydrobromic acid, hydriodic acid, phosphorous acid and the like, as well as salts derived from organic acids such as aliphatic mono- and di-carboxylic acids, phenyl-substituted alkanolic acids, hydroxy-alkanoic and -alkanedioic acids, aromatic acids, aliphatic and aromatic sulfonic acids, etc. Such pharmaceutically acceptable salts thus include sulfate, metaphosphate, pyrophosphate, chloride, bromide, iodide, fluoride, oxalate, maleate, benzene-sulfonate, toluenesulfonate, chlorobenzenesulfonate, methanesulfonate, propanesulfonate, naphthalene-1-sulfonate, naphthalene-2-sulfonate and the like. The preferred salts are those derived from inorganic acids, especially hydrochloric acid.

Certain of the compounds of formula (I) can be prepared by standard acylation procedures well known in the art as summarized by the following scheme:



wherein X is a good leaving group.

Although any of a number of general acylation techniques may be employed, it is preferred that an acid halide (II), X is bromo or chloro) and the aniline (III) be reacted in a nonreactive solvent, such as tetrahydrofuran or dimethylformamide, preferably in the presence of an acid scavenger such as a carbonate, especially potassium carbonate, or an organic base, such as triethylamine or pyridine. Although it is preferred that the reactants be added in the approximate molar ratio of about 1.25:1 (II:III), other ratios are operative. The reaction is carried out from about room temperature up to the reflux temperature of the reaction mixture. Under the preferred conditions of approximately 25°C, the reaction is generally complete in 1-2 hours.

Specifically, the free carboxylic acid form of benzoyl compound (Formula II) or its acid salt can be combined with a condensing agent to acylate the aniline ring (Formula III). Suitable condensing agents include N,N-disubstituted carbodiimides such as N,N-dicyclohexylcarbodiimide, N,N-diethylcarbodiimide, N,N-di-(n-propyl)carbodiimide, N,N-di-(isopropyl)carbodiimide, N,N-diallylcarbodiimide, N,N-bis(p-dimethylaminophenyl)carbodiimide, N-ethyl-N-(4'-ethylmorpholinyl)carbodiimide and the like, other suitable carbodiimides being disclosed by Sheehan in U.S. Pat. No. 2,938,892 and by Hofmann et al. U.S. Patent No. 3,065,224; and azolides such as N,N-carbonylimidazole, N,N-thionylimidazol, etc. Also, dehydrating agents such as phosphorus oxychloride, alkoxycarbonylenes, etc. and 2-halogeno-pyridinium salts (such as 2-chloropyridinium methyl iodide, 2-fluoropyridinium methyl iodide, etc.) may be used to couple the free acid or its acid salt with the aniline ring.

Another acylation method entails first converting the free carboxylic acid form (or the corresponding salt) of the benzoyl ring to the active ester derivative which derivative is in turn used to acylate the aniline ring. The active ester derivative is formed by esterifying the free acid form of the benzoyl ring with groups such as p-nitrophenyl, 2,4-dinitrophenyl, trichlorophenyl, pentachlorophenyl, N-succinimide, N-maleic imide, N-phthalimide, vinyl, propargyl, cyanomethyl, methoxy-methyl, pyranyl, pyridyl, piperidyl, 1H-benzotriazol-1-yl or 6-chloro-1H-benzotriazol-1-yl and also with groups that form mixed acid anhydrides, i.e. acylating the carboxylic acid of the benzoyl ring with groups such as methoxycarbonyl, ethoxycarbonyl, iso-butoxycarbonyl, trichloromethylcarbonyl, and iso-but-2-ylcarbonyl.

Alternatively, the benzoyl ring can be acylated with the N-ethoxycarbonyl-2-ethoxy-1,2-dihydroquinoline (EEDQ) derivative of the aniline ring. In general, the free acid form of the aniline ring and EEDQ are reacted in an inert, polar organic solvent (e.g. tetrahydrofuran, acetonitrile, etc.). The resultant EEDQ derivative is used in situ to acylate the aniline ring.

The amino substituted compounds of this invention may also be prepared from the corresponding fluoro compound (i.e. a compound of general structure I except that R₁ is fluoro) by reacting with imidazole or an amine of the formula R₂R₃NH. In general, this reaction is accomplished by reacting a large excess of the amine with the fluoro intermediate, preferably in the presence of a non-reactive solvent such as dimethylsulfoxide, tetrahydrofuran, or the like. The reaction is generally carried out at temperatures from about 100-150°C in a sealed reaction vessel. At the preferred reaction temperature of 150°C, the reaction is generally

complete within approximately 18 hours.

Other compounds of the invention may also be derived from related compounds. For example, the nitrile compounds of this invention ($R_1 = -CN$) may be transformed into the corresponding aminomethyl analogs ($R_1 = H_2NCH_2-$) upon catalytic hydrogenation of the nitrile. Generally, this transformation is accomplished by hydrogenating the nitrile in a nonreactive solvent, such as tetrahydrofuran, in the presence of a catalyst, for example 5% palladium on carbon, until the theoretical amount of hydrogen has been consumed.

Similarly, the nitriles can be hydrolyzed to the corresponding primary amide compounds of this invention ($R_1 = H_2NCO-$). The preferred method of accomplishing this transformation involves heating the nitrile at reflux in an alcoholic solution of 3-4 equivalents of a strong base, such as sodium or potassium hydroxide. When employing the preferred alcohol t-butanol, the reaction is usually complete in about an hour.

The thio derivatives and intermediates of this invention (p is 0) may be transformed into the corresponding sulfoxide (p is 1) compounds upon treatment with a mild oxidizing agent, such as hydrogen peroxide in methanol, meta-chloroperoxybenzoic acid (MCPBA) in methylene chloride at $0^\circ C$, or an alkali metal periodate in aqueous alcohol. The corresponding sulfones (p is 2) are prepared from the thio or sulfoxide compounds on treatment with a strong oxidizing agent such as hydrogen peroxide in acetic acid or *m*-chloroperoxybenzoic acid in methylene chloride at $20-30^\circ C$.

The hydroxy compounds ($R_1 = OH$) can be prepared from the corresponding methoxy derivatives by standard demethylation techniques. The preferred method comprises the use of boron tribromide in a nonreactive solvent such as methylene chloride as provided in Example 15 which follows.

The intermediates of Formulas (I) and (II) and other necessary reagents for preparing the compounds employed in this invention are commercially available, are known in the art, or can be prepared by methods taught in the literature.

The *p*-substituted benzamides of Formula (I) are anticonvulsant agents and may be administered by various routes including the oral, rectal, transdermal, subcutaneous, intravenous, intramuscular, or intranasal routes, being usually employed in the form of a pharmaceutical composition. It is a special feature of these compounds that they are effective following oral administration. The invention includes a pharmaceutical composition comprising from about 1% to about 95% by weight of a *p*-aminobenzamide of Formula (I), or a pharmaceutically acceptable acid addition salt thereof, associated with a pharmaceutically acceptable carrier.

In making the compositions of the present invention, the active ingredient will usually be mixed with a carrier, or diluted by a carrier, or enclosed within a carrier which may be in the form of a capsule, sachet, paper or other container. When the carrier serves as a diluent, it may be a solid, semi-solid or liquid material which acts as a vehicle, excipient or medium for the active ingredient. Thus, the composition can be in the form of tablets, pills, powders, lozenges, sachets, cachets, elixirs, suspensions, emulsions, solutions, syrups, aerosols (as a solid or in a liquid medium), ointments containing for example up to 10% by weight of the active compound, soft and hard gelatin capsules, suppositories, sterile injectable solutions and sterile packaged powders.

Some examples of suitable carriers and diluents include lactose, dextrose, sucrose, sorbitol, mannitol, starches, gum acacia, calcium phosphate, alginates, tragacanth, gelatin, calcium silicate, microcrystalline cellulose, polyvinylpyrrolidone, cellulose, water, syrup, methyl cellulose, methyl- and propylhydroxybenzoates, talc, magnesium stearate and mineral oil. The formulations can additionally include lubricating agents, wetting agents, emulsifying and suspending agents, preserving agents, sweetening agents or flavoring agents. The compositions of the invention may be formulated so as to provide quick, sustained or delayed release of the active ingredient after administration to the patient.

The compositions are preferably formulated in a unit dosage form, each dosage containing from about 5 to 500 mg, more usually 25 to 300 mg, of the active ingredient. The term "unit dosage form" refers to physically discrete units suitable as unitary dosages for human subjects and other mammals, each unit containing a predetermined quantity of active material calculated to produce the desired therapeutic effect, in association with the required pharmaceutical carrier.

The active compounds are effective over a wide dosage range. For example, dosages per day will normally fall within the range of about 0.5 to 300 mg/kg of body weight. In the treatment of adult humans, the range of about 1 to 50 mg/kg, in single or divided doses, is preferred. However, it will be understood that the amount of the compound actually administered will be determined by a physician, in the light of the relevant circumstances including the condition to be treated, the choice of compound to be administered, the chosen route of administration, the age, weight, and response of the individual patient, and the severity of the patient's symptoms.

The following examples further illustrate the preparation of the intermediates, compounds, and formulations of this invention. The examples are illustrative only and are not intended to limit the scope of the invention in any way.

5 Example 1

N-(2,6-dimethylphenyl)-4-(trifluoromethyl)benzamide

10 A solution of 25 g of 4-trifluoromethylbenzoyl chloride in tetrahydrofuran was added to 14.5 g of 2,6-dimethylaniline and 16.7 ml of triethylamine in tetrahydrofuran. The reaction was stirred ambient temperature overnight, chilled, and filtered. The filtrate was evaporated in vacuo and the residue therefrom was dissolved in chloroform, washed sequentially with 1M hydrochloric acid, 1M sodium hydroxide, water, and a saturated sodium chloride solution, dried over sodium sulfate, filtered, and evaporated in vacuo. Crystallization from methanol provided the desired title product in 85% yield, m.p. 206-207 ° C.

15

Analysis for C ₁₅ H ₁₄ F ₃ NO:			
Calculated:	C, 65.52;	H, 4.81;	N, 4.78;
Found:	C, 65.62;	H, 4.97;	N, 4.88.

20

Examples 2-5

25 The following benzamides were prepared from the appropriately substituted benzoyl chloride according to the procedure of Example 1.

2. 4-Cyano-N-(2,6-dimethylphenyl)benzamide, 67% yield, m.p. 185-187 ° C.

30

Analysis for C ₁₅ H ₁₄ N ₂ O:			
Calculated:	C, 76.78;	H, 5.64;	N, 11.19;
Found:	C, 76.84;	H, 5.36;	N, 11.11.

36

3. N-(2,6-dimethylphenyl)-4-methylbenzamide, 83% yield, m.p. 163-164 ° C.

40

Analysis for C ₁₅ H ₁₇ NO:			
Calculated:	C, 80.30;	H, 7.16;	N, 5.85;
Found:	C, 80.47;	H, 7.02;	N, 5.69.

4. N-(2,6-dimethylphenyl)-4-methoxybenzamide, 94% yield, m.p. 168-170 ° C.

45

Analysis for C ₁₅ H ₁₇ NO ₂ :			
Calculated:	C, 75.27;	H, 6.71;	N, 5.49;
Found:	C, 75.15;	H, 6.58;	N, 5.19.

5. N-(2,6-dimethylphenyl)-4-(methylthio)benzamide, 76% yield, m.p. 183-185 ° C.

50

Analysis for C ₁₅ H ₁₇ NOS:				
Calculated:	C, 70.81;	H, 6.31;	N, 5.16;	S, 11.82;
Found:	C, 71.08;	H, 6.48;	N, 5.19;	S, 11.99.

55

Example 6

4-(Dimethylamino)-N-(2,6-dimethylphenyl)benzamide

5 A. Preparation of N-(2,6-dimethylphenyl)-4-fluorobenzamide.

The subtitle intermediate was prepared in 68% yield from 4-fluorobenzoyl chloride following the procedure of Example 1, m.p. 180-181 °C.

10

Analysis for $C_{15}H_{14}FNO$:			
Calculated:	C, 74.06;	H, 5.80;	N, 5.76;
Found:	C, 73.83;	H, 5.76;	N, 5.76.

15

B. Preparation of 4-(dimethylamino)-N-(2,6-dimethylphenyl)benzamide.

Ten grams of N-(2,6-dimethylphenyl)-4-fluorobenzamide were dissolved in 50 ml of dimethylsulfoxide in a high pressure/temperature bomb. Anhydrous dimethylamine (18.5 g) was added and the reaction vessel sealed and heated at 150 °C for 18 hours. The bomb was cooled and the contents poured into water. The mixture was extracted with chloroform. The organic layer was washed with water and a saturated sodium chloride solution, dried over anhydrous sodium sulfate, and concentrated in vacuo. The resulting residue was crystallized from methanol/water affording the desired title product in 56% yield, m.p. 215-217 °C.

25

Analysis for $C_{17}H_{20}N_2O$:			
Calculated:	C, 76.09;	H, 7.51;	N, 10.44;
Found:	C, 75.85;	H, 7.52;	N, 10.15.

30

Examples 7-9

The following products were prepared according to the procedure of Example 6B employing the appropriate amine.

35

7. N-(2,6-dimethylphenyl)-4-(ethylamino)benzamide, 56% yield, m.p. 145-147 °C.

40

Analysis for $C_{17}H_{20}N_2O$:			
Calculated:	C, 76.09;	H, 7.51;	N, 10.44;
Found:	C, 75.86;	H, 7.27;	N, 10.14.

45

8. N-(2,6-dimethylphenyl)-4-(methylamino)benzamide, 35% yield, m.p. 163-164 °C.

50

Analysis for $C_{16}H_{18}N_2O$:			
Calculated:	C, 75.56;	H, 7.13;	N, 11.01;
Found:	C, 75.80;	H, 7.18;	N, 10.99.

9. N-(2,6-dimethylphenyl)-4-(methylpropylamino)benzamide, 49% yield, m.p. 159-160 °C.

55

Analysis for $C_{19}H_{24}N_2O$:			
Calculated:	C, 76.99;	H, 8.16;	N, 9.45;
Found:	C, 76.78;	H, 7.96;	N, 9.29.

Example 10

N-(2,6-dimethylphenyl)-4-(1H-imidazol-1-yl)benzamide hydrochloride

- 5 Imidazole (3.5 g) was dissolved in a small volume of dimethylformamide and added to a slurry of 1.81 g of 60% sodium hydride in oil in dimethylformamide. Five grams of N-(2,6-dimethylphenyl)-4-fluorobenzamide in a small volume of dimethylformamide was added to the reaction mixture. The reaction was heated at 100 °C for 18 hours, cooled, and poured into water. The mixture was extracted with ethyl acetate. The organic portion was washed with water and a saturated sodium chloride solution, dried over sodium sulfate, and concentrated *in vacuo*. The residue was chromatographed over silica gel eluting with an ethyl acetate and hexane gradient. The solvents of the combined appropriate fractions were removed *in vacuo*. The hydrochloride salt was generated by adding gaseous hydrogen chloride into a solution of the residue in ethanol. Crystallization of the recovered product from ethanol/ether provided the title product in 62% yield, m.p. 259-261 °C.

16

Analysis for $C_{18}H_{17}N_3O \cdot HCl$:			
Calculated:	C, 65.95;	H, 5.53;	N, 12.82;
Found:	C, 62.72;	H, 5.34;	N, 12.87.

20

Example 11

4-(Aminomethyl)-N-(2,6-dimethylphenyl)benzamide hydrochloride

- 25 Ten grams of 4-cyano-N-(2,6-dimethylphenyl)benzamide were dissolved in 150 ml of tetrahydrofuran and hydrogenated over 5% palladium-on-carbon catalyst at 60 psi until the theoretical amount of hydrogen had been taken up. The catalyst was removed by filtration and the solvent evaporated *in vacuo* affording an oil. The oil was chromatographed over silica gel eluting with a methanol in methylene chloride gradient. The appropriate fractions were combined and concentrated *in vacuo* to provide a foam. The hydrochloride salt was generated by dissolving the foam in ethanol and bubbling in anhydrous hydrogen chloride gas. After evaporation, the hydrochloride salt was crystallized from ethanol affording the title product in 61% yield, m.p. 277-279 °C.

36

Analysis for $C_{16}H_{18}N_2O \cdot HCl$:			
Calculated:	C, 66.09;	H, 6.59;	N, 9.63;
Found:	C, 65.95;	H, 6.62;	N, 9.71.

40

Example 12

N-(2,6-Dimethylphenyl)-1,4-benzenedicarboxamide

- 45 Ten grams of 4-cyano-N-(2,6-dimethylphenyl)benzamide and 3 grams of finely powdered potassium hydroxide were slurried in t-butanol and heated at reflux for 50 minutes. The homogeneous mixture was poured into a saturated sodium chloride solution and extracted into chloroform. Material which was insoluble in both the organic and water phases was recovered by filtration, crystallized from methanol, and provided the title compound in 43% yield, m.p. 246-248 °C.

50

Analysis for $C_{16}H_{16}N_2O_2$:			
Calculated:	C, 71.62;	H, 6.09;	N, 10.44;
Found:	C, 71.33;	H, 6.01;	N, 10.38.

56

Example 13

N-(2,6-dimethylphenyl)-4-(methylsulfinyl)benzamide

- 5 Ten grams of N-(2,6-dimethylphenyl)-4-(methylthio)benzamide were dissolved in a small volume of chloroform and chilled to 0°C. A solution of 7.9 g of m-chloroperoxybenzoic acid in chloroform was added in dropwise fashion. The reaction was stirred at room temperature for 1 hour, washed with a sodium bicarbonate solution, water, and a saturated chloride solution, dried over sodium sulfate and evaporated in vacuo. The resulting foam was chromatographed over silica gel eluting with an ethyl acetate in hexane
10 gradient. The appropriate fractions were combined and the solvent removed in vacuo and the resulting residue was crystallized from ethyl acetate/hexane providing the desired title product in 59% yield, m.p. 144-146°C.

15

Analysis for C ₁₆ H ₁₇ NO ₂ S:			
Calculated:	C, 66.87;	H, 5.96;	N, 4.87;
Found:	C, 67.10;	H, 6.09;	N, 4.77.

20

Example 14

N-(2,6-dimethylphenyl)-4-(methylsulfonyl)benzamide

- 25 The title product was prepared in 86% yield following the procedure of Example 13 employing 7 g of the methylthiobenzamide and 10.6 g of m-chloroperoxybenzoic acid, m.p. 164-165.5°C.

30

Analysis for C ₁₆ H ₁₇ NO ₃ S:			
Calculated:	C, 63.34;	H, 5.65;	N, 4.62;
Found:	C, 63.13;	H, 5.71;	N, 4.55.

35

Example 15

N-(2,6-dimethylphenyl)-4-hydroxybenzamide

- 36 A solution of 6.4 g of N-(2,6-dimethylphenyl)-4-methoxybenzamide in methylene chloride was cooled to -75°C. Boron tribromide (25 g) was added over a 15 minute period. The reaction mixture was allowed to
40 warm over 2 hours and then heated at reflux for 2 hours. The reaction was again cooled to -75°C and 50 ml of water were added. The mixture was allowed to warm and the layers were separated. The organic layer was dried over sodium sulfate and evaporated in vacuo. The residue was crystallized from methanol/water affording the desired title product in 80% yield, m.p. 232-234°C.

45

Analysis for C ₁₅ H ₁₅ NO ₂ :			
Calculated:	C, 74.67;	H, 6.27;	N, 5.81;
Found:	C, 74.39;	H, 6.14;	N, 5.58.

50

The following formulation examples may employ as active compounds any of the pharmaceutical compounds of the invention or their pharmaceutically acceptable salts.

55

Example 16

Hard gelatin capsules are prepared using the following ingredients:

5

10

	<u>Quantity (mg/capsule)</u>
4-Cyano-N-(2,6-dimethyl-phenyl)benzamide	250
Starch dried	200
Magnesium stearate	10

15

The above ingredients are mixed and filled into hard gelatin capsules in 460 mg quantities.

Example 17

A tablet formula is prepared using the ingredients below:

20

25

30

	<u>Quantity (mg/tablet)</u>
4-(Dimethylamino)-N-(2,6-dimethylphenyl)benzamide	250
Cellulose, microcrystalline	400
Silicon dioxide, fumed	10
Stearic acid	5

The components are blended and compressed to form tablets each weighing 665 mg.

Example 18

35

An aerosol solution is prepared containing the following components:

40

45

	<u>Weight %</u>
N-(2,6-dimethylphenyl)-4-methoxybenzamide	0.25
Ethanol	29.75
Propellant 22	70.00
(Chlorodifluoromethane)	

50

The active compound is mixed with ethanol and the mixture added to a portion of the propellant 22, cooled to -30° C and transferred to a filling device. The required amount is then fed to a stainless steel container and diluted with the remainder of the propellant. The valve units are then fitted to the container.

55

Example 19

Tablets each containing 60 mg of active ingredient are made up as follows:

5	N-(2,6-dimethylphenyl)-4-(ethylamino)benzamide	60 mg
	Starch	45 mg
10	Microcrystalline cellulose	35 mg
	Polyvinylpyrrolidone	
	(as 10% solution in water)	4 mg
	Sodium carboxymethyl starch	4.5 mg
15	Magnesium stearate	0.5 mg
	Talc	<u>1 mg</u>
	Total	150 mg

20 The active ingredient, starch and cellulose are passed through a No. 45 mesh U.S. sieve and mixed thoroughly. The solution of polyvinylpyrrolidone is mixed with the resultant powders which are then passed through a No. 14 mesh U.S. sieve. The granules so produced are dried at 50-60°C and passed through a No. 18 mesh U.S. sieve. The sodium carboxymethyl starch, magnesium stearate and talc, previously
 25 passed through a No. 60 mesh U.S. sieve, are then added to the granules which, after mixing, are compressed on a tablet machine to yield tablets each weighing 150 mg.

Example 20

30 Capsules each containing 80 mg of medicament are made as follows:

	N-(2,6-dimethylphenyl)-4-(methylamino)benzamide sulfate	80 mg
35	Starch	59 mg
	Microcrystalline cellulose	59 mg
	Magnesium stearate	<u>2 mg</u>
40	Total	200 mg

The active ingredient, cellulose, starch and magnesium stearate are blended, passed through a No. 45 mesh U.S. sieve, and filled into hard gelatin capsules in 200 mg quantities.

Example 21

Suppositories each containing 225 mg of active ingredient are made as follows:

50	N-(2,6-dimethylphenyl)-4-(methylpropylamino)benzamide	225 mg
	Saturated fatty acid glycerides to	2,000 mg

The active ingredient is passed through a No. 60 mesh U.S. sieve and suspended in the saturated fatty acid glycerides previously melted using the minimum heat necessary. The mixture is then poured into a
 55 suppository mold of nominal 2 g capacity and allowed to cool.

Example 22

Suspensions each containing 50 mg of medicament per 5 ml dose are made as follows:

N-(2,6-dimethylphenyl)-4-hydroxybenzamide	50 mg
Sodium carboxymethyl cellulose	50 mg
Syrup	1.25 ml
Benzoic acid solution	0.10 ml
Flavor	q.v.
Color	q.v.
Purified water to	5 ml

The medicament is passed through a No. 45 mesh U.S. sieve and mixed with the sodium carboxymethyl cellulose and syrup to form a smooth paste. The benzoic acid solution, flavor and color are diluted with some of the water and added, with stirring. Sufficient water is then added to produce the required volume.

The compounds of Formula (I) are anticonvulsant agents with a large therapeutic ratio and long half-life and are therefore useful in the treatment and prevention of convulsions in mammals. Moreover, the anticonvulsant compounds of this invention, in contrast to some anticonvulsant benzamides taught in the art, lack genetic toxicity and do not cause hemolysis. The compounds are effective against tonic extensor seizures elicited by maximal electroshock and should therefore be useful for treating generalized tonic-clonic ("grand mal"), cortical focal, complex partial (temporal lobe epilepsy), simple partial (focal motor), and post-traumatic seizures in humans. This activity is demonstrated in the electroshock induced convulsion inhibition assay which follows.

In the electroshock induced convulsion inhibition assay (E.S.), the compound to be tested was suspended in acacia and administered by gavage to each of ten Cox standard strain albino male mice (18-24 g) at the dose level being investigated. Thirty to 180 minutes after compound administration, the mice were subjected to a 0.1 second, 50 milliamper electroshock through corneal electrodes. The animals were examined and evaluated immediately after the electroshock for the occurrence of clonic, flexor tonic, or extensor tonic convulsions, or death and the ED_{50} was determined for each compound as the dose which inhibited the occurrence of extensor tonic convulsions in one half of the animals immediately after the electroshock. For comparison, 18 milliamperes was usually sufficient to produce extensor tonic convulsions in about half of the control animals; at 50 milliamperes, almost all control animals (receiving vehicle only) died. The test results summarized in Table I are reported as the ED_{50} values at the time interval found to provide an optimal response after dosing.

Table I

Anti-convulsant Activity of compounds of Formula (I)

Example No.	Electroshock ED ₅₀ (mg/kg)*	Time after dosing (minutes)**
1	ca. 225	60
2	13.2	60
3	ca. 250	30
4	15	30
5	ca. 75	180
6	3.65	120
7	2.45	60
8	2.0	120
9	4.6	120
10	ca. 50	120
11	38	60
12	ca. 75	60
13	13	60
14	14	60
15	11.2	60


* oral dose (gavage)-See text for methodology.

** Time (between dosing and administration of the electroshock) providing an optimal response.

Claims

Claims for the following Contracting States : AT, BE, CH, DE, FR, GB, IT, LI, LU, NL, SE

1. A pharmaceutical composition which comprises a compound of Formula (I):




wherein R₁ is hydroxy, C₁-C₄ alkoxy, -S(O)_p-(C₁-C₄ alkyl) where p is 0 to 2, trifluoromethyl, C₁-C₄ alkyl, aminomethyl, cyano, primary amido, 1-imidazolyl, or -NR₃R₄, where R₃ is hydrogen or C₁-C₃ alkyl and R₄ is C₁-C₃ alkyl, and

R₂ is methyl, methoxy, trifluoromethyl, hydroxymethyl, or chloro, or a pharmaceutically acceptable salt thereof, associated with one or more pharmaceutically-acceptable carriers or excipients therefor.


2. A pharmaceutical composition as claimed in claim 1 provided that, when R₃ is hydrogen, R₄ can only be methyl or ethyl and R₂ can only be methyl.
3. A compound of Formula (I) as defined in claim 1 or 2, or a pharmaceutically-acceptable salt thereof, for use in treating or preventing convulsions in mammals in need of such treatment.

4. A compound of the Formula (I):




wherein R₁ is -S(O)_p-(C₁-C₆ alkyl) where p is 0 to 2, trifluoromethyl, primary amido, cyano, 1-imidazolyl, or -NR₃R₄, where R₃ is hydrogen or C₁-C₃ alkyl, and R₄ is C₁-C₃ alkyl, and R₂ is methyl, methoxy, trifluoromethyl, hydroxymethyl, or chloro; or a pharmaceutically acceptable salt thereof.

5. A compound of Formula (I) as claimed in claim 4 provided that, when R₃ is hydrogen, R₄ can only be methyl or ethyl and R₂ can only be methyl.
6. A compound as claimed in claim 5 of the Formula (I) wherein R₂ is methyl.
7. 4-(Dimethylamino)-N-(2,6-dimethylphenyl)benzamide or a pharmaceutically acceptable salt thereof.
8. N-(2,6-Dimethylphenyl)-4-(methoxy)benzamide or a pharmaceutically acceptable salt thereof.
9. N-(2,6-Dimethyl phenyl)-4-(cyano)benzamide or a pharmaceutically acceptable salt thereof.
10. A process for preparing a compound of Formula (I) as claimed in any one of claims 4 to 9 which comprises
- a) acylating an aniline compound of Formula (III)




with a benzoyl compound of Formula (II)



wherein R₁ and R₂ are as described in Formula (I) of claim 1 and X is a good leaving group, to produce a compound of Formula (I); or

b) reacting a 4-fluoro compound of the formula



with an amine of the formula




or a 1H-imidazole ring, wherein R_2 , R_3 , and R_4 are the same as Formula (I) of claim 1 at elevated temperatures to produce a compound of Formula (I) wherein R_1 is a group of the formula $-\text{NR}_3\text{R}_4$ or a 1H-1-imidazo ring; or


c) reducing a compound of Formula (I) of claim 1 wherein R_1 is a cyano group with hydrogen over a transition metal catalyst to produce a compound of Formula (I) wherein R_1 is an aminomethyl group; or

d) hydrolyzing a compound of Formula (I) of claim 1 wherein R_2 is as defined for claim 1 and wherein R_1 is a cyano group to produce a compound of claim 1 wherein R_1 is a primary amido group; or

e) oxidizing a compound of Formula (I) of claim 1 wherein R_2 is as defined for claim 1 and R_1 is a group of the formula




to produce a compound of claim 1 wherein R_1 is a group of the formula



wherein p is one or two.

25 Claims for the following Contracting States : ES, GR


1. A process for preparing a compound of the Formula (I):




wherein R_1 is $-\text{S}(\text{O})_p-(\text{C}_1-\text{C}_4 \text{ alkyl})$ where p is 0 to 2, trifluoromethyl, primary amido, cyano, 1-imidazolyl, or $-\text{NR}_3\text{R}_4$, where R_3 is hydrogen or $\text{C}_1-\text{C}_3 \text{ alkyl}$, and R_4 is $\text{C}_1-\text{C}_3 \text{ alkyl}$, and

R_2 is methyl, methoxy, trifluoromethyl, hydroxymethyl, or chloro; or a pharmaceutically acceptable salt thereof; which process comprises


- a) acylating an aniline compound of Formula (III)



with a benzoyl compound of Formula (II)




wherein X is a good leaving group; or
b) reacting a 4-fluoro compound of the formula




with an amine of the formula



or a 1H-imidazole ring, at elevated temperatures to produce a compound of Formula (I) wherein R_1 is a group of the formula $-\text{NR}_3\text{R}_4$ or a 1H-1-imidazo ring; or
c) reducing a compound of Formula (I) wherein R_1 is a cyano group with hydrogen over a transition metal catalyst to produce a compound of Formula (I) wherein R_1 is an aminomethyl group; or
d) hydrolyzing a compound of Formula (I) wherein R_1 is a cyano group to produce a compound of Formula (I) wherein R_1 is a primary amido group; or
e) oxidizing a compound of Formula (I) wherein R_1 is a group of the formula




to produce a compound of Formula I wherein R_1 is a group of the formula




wherein p is one or two.

to produce a compound of Formula I wherein R_1 is a group of the formula



wherein p is one or two.

2. A process as claimed in claim 1 provided that, when R_3 is hydrogen, R_4 can only be methyl or ethyl and R_2 can only be methyl.
3. A process according to claim 2 for preparing 4-(dimethylamino)-N-(2,6-dimethylphenyl)benzamide or a pharmaceutically acceptable salt thereof.
4. A process according to claim 2 for preparing N-(2,6-dimethylphenyl)-4-(methoxy)benzamide or a pharmaceutically acceptable salt thereof.
5. A process according to claim 2 for preparing N-(2,6-dimethylphenyl)-4-(cyano)benzamide or a pharmaceutically acceptable salt thereof.
6. A process for preparing a pharmaceutical composition which comprises admixing a compound of Formula (I):



10 wherein R_1 is hydroxy, C_1 - C_4 alkoxy, $-S(O)_p-(C_1-C_4 \text{ alkyl})$ where p is 0 to 2, trifluoromethyl, C_1 - C_4 alkyl, aminomethyl, cyano, primary amido, 1-imidazolyl, or $-NR_3R_4$, where R_3 is hydrogen or C_1 - C_3 alkyl and R_4 is C_1 - C_3 alkyl, and

15 R_2 is methyl, methoxy, trifluoromethyl, hydroxymethyl, or chloro,
or a pharmaceutically acceptable salt thereof, with one or more pharmaceutically-acceptable carriers or excipients therefor.


7. A process as claimed in claim 6 provided that, when R_3 is hydrogen, R_4 can only be methyl or ethyl and R_2 can only be methyl.

20 8. A process as claimed in claim 7 wherein the compound of Formula (I) is N-(2,6-dimethylphenyl)-4-(methoxy)benzamide or a pharmaceutically acceptable salt thereof.

Patentansprüche

25 Patentansprüche für folgende Vertragsstaaten : AT, BE, CH, DE, FR, GB, IT, LI, LU, NL, SE

1. Pharmazeutische Zusammensetzung umfassend eine Verbindung der Formel (I):




40 worin R_1 ein Hydroxy-, C_1 - C_4 -Alkoxy-, $-S(O)_p-(C_1-C_4\text{-Alkyl})$ - worin p bis 2 ist, Trifluormethyl-, C_1 - C_4 -Alkyl-, Aminomethyl-, Cyano-, primärer Amido-, 1-Imidazolylrest oder $-NR_3R_4$ ist, worin R_3 Wasserstoff oder ein C_1 - C_3 -Alkylrest und R_4 ein C_1 - C_3 -Alkylrest ist und R_2 ein Methyl-, Methoxy-, Trifluormethyl-, Hydroxymethyl- oder Chlorrest ist, oder ein pharmazeutisch annehmbares Salz davon zusammen mit einem oder mehreren pharmazeutisch annehmbaren Trägern oder Hilfsstoffen dafür.

45 2. Pharmazeutische Zusammensetzung nach Anspruch 1 mit dem Vorbehalt, daß dann wenn R_3 Wasserstoff ist, R_4 nur ein Methylrest oder Ethylrest sein kann und R_2 nur ein Methylrest sein kann.

3. Verbindung der Formel (I) wie in Anspruch 1 oder 2 definiert oder ein pharmazeutisch annehmbares Salz davon zur Verwendung zur Behandlung oder Verhütung von Anfällen bei Säugetieren, die eine solche Behandlung benötigen.


50

4. Verbindung der Formel (I):




worin R_1 ein $-S(O)_p-(C_1-C_4\text{-Alkyl})-$, worin p 0 bis 2 ist, Trifluormethyl-, primärer Amido-, Cyano-, 1-Imidazolylrest oder $-NR_3R_4$ ist, worin R_3 Wasserstoff oder ein C_1-C_3 -Alkylrest und R_4 ein C_1-C_3 -Alkylrest ist und R_2 ein Methyl-, Methoxy-, Trifluormethyl-, Hydroxymethyl- oder Chlorrest ist; oder ein pharmazeutisch annehmbares Salz davon.

5. Verbindung der Formel (I) nach Anspruch 4, mit dem Vorbehalt, daß dann wenn R_3 Wasserstoff ist, R_4 nur ein Methyl- oder Ethylrest sein kann und R_2 nur ein Methylrest sein kann.
6. Verbindung nach Anspruch 5 der Formel (I), worin R_2 ein Methylrest ist.
7. 4-(Dimethylamino)-N-(2,6-dimethylphenyl)-benzamid oder ein pharmazeutisch annehmbares Salz davon.
8. N-(2,6-Dimethylphenyl)-4-(methoxy)benzamid oder ein pharmazeutisch annehmbares Salz davon.
9. N-(2,6-Dimethylphenyl)-4-(cyano)benzamid oder ein pharmazeutisch annehmbares Salz davon.
10. Verfahren zur Herstellung einer Verbindung der Formel (I) nach einem der Ansprüche 4 bis 9 umfassend, daß man
- a) eine Anilinverbindung der Formel (III)




mit einer Benzoylverbindung der Formel (II)



acyliert, worin R_1 und R_2 wie in Formel (I) von Anspruch 1 beschrieben sind und X eine gute Abgangsgruppe ist, um eine Verbindung der Formel (I) herzustellen, oder

b) eine 4-Fluorverbindung der Formel



mit einem Amin der Formel HNR_3R_4 oder einem 1H-Imidazolring, worin R_2 , R_3 und R_4 wie für Formel (I) in Anspruch 1 definiert ist, bei erhöhten Temperaturen umsetzt, um eine Verbindung der Formel (I) herzustellen, worin R_1 eine Gruppe der Formel $-\text{NR}_3\text{R}_4$ oder ein 1H-1-Imidazolring ist, oder


c) eine Verbindung der Formel (I) von Anspruch 1, worin R_1 eine Cyanogruppe ist, mit Wasserstoff über einem Übergangsmetallkatalysator reduziert, um eine Verbindung der Formel (I) herzustellen, worin R_1 eine Aminomethylgruppe ist, oder

d) eine Verbindung der Formel (I) nach Anspruch 1, worin R_2 wie für Anspruch 1 definiert ist und worin R_1 eine Cyanogruppe ist, hydrolysiert, um eine Verbindung nach Anspruch 1 herzustellen, worin R_1 eine primäre Amidogruppe ist, oder

e) eine Verbindung der Formel (I) von Anspruch 1, worin R_2 wie für Anspruch 1 definiert ist und R_1 eine Gruppe der Formel $-\text{S}(\text{O})_{p-1}-(\text{C}_1-\text{C}_4-\text{Alkyl})$ ist, oxidiert, um eine Verbindung der Formel (I) herzustellen, worin R_1 eine Gruppe der Formel $-\text{S}(\text{O})_p-(\text{C}_1-\text{C}_4-\text{Alkyl})$ bedeutet, worin p 1 oder 2 ist.


Patentansprüche für folgende Vertragsstaaten : ES, GR

1. Verfahren zur Herstellung einer Verbindung der Formel (I):




worin R_1 ein $-\text{S}(\text{O})_{p-1}-(\text{C}_1-\text{C}_4-\text{Alkyl})$, worin p 0 bis 2 ist, Trifluormethyl-, primärer Amido-, Cyano-, 1-Imidazolylrest oder $-\text{NR}_3\text{R}_4$ ist, worin R_3 Wasserstoff oder ein C_1-C_3 -Alkylrest und R_4 ein C_1-C_3 -Alkylrest ist und R_2 ein Methyl-, Methoxy-, Trifluormethyl-, Hydroxymethyl-, oder Chlorrest ist, oder eines pharmazeutisch annehmbaren Salzes davon, wobei das Verfahren umfaßt, daß man


a) eine Anilinverbindung der Formel (III)



mit einer Benzoylverbindung der Formel (II)



acyliert, worin X eine gute Abgangsgruppe ist, oder
b) eine 4-Fluorverbindung der Formel



mit einem Amin der Formel HNR_3R_4 oder einem 1H-Imidazolring, bei erhöhten Temperaturen umsetzt, um eine Verbindung der Formel (I) herzustellen, worin R_1 eine Gruppe der Formel $-\text{NR}_3\text{R}_4$ oder ein 1H-1-Imidazolring ist, oder

c) eine Verbindung der Formel (I), worin R_1 eine Cyanogruppe ist, mit Wasserstoff über einem Übergangsmetallkatalysator reduziert, um eine Verbindung der Formel (I) herzustellen, worin R_1 eine Aminomethylgruppe ist, oder

d) eine Verbindung der Formel (I), worin R_1 eine Cyanogruppe ist, hydrolysiert, um eine Verbindung der Formel 1 herzustellen, worin R_1 eine primäre Amidogruppe ist, oder

e) eine Verbindung der Formel (I), worin R_1 eine Gruppe der Formel $-\text{S}(\text{O})_p-1-(\text{C}_1-\text{C}_4-\text{Alkyl})$ ist, oxidiert, um eine Verbindung der Formel (I) herzustellen, worin R_1 eine Gruppe der Formel $-\text{S}(\text{O})_p-(\text{C}_1-\text{C}_4-\text{Alkyl})$ bedeutet, worin p 1 oder 2 ist.


2. Verfahren nach Anspruch 1 mit dem Vorbehalt, daß dann wenn R_3 Wasserstoff ist, R_4 nur ein Methyl- oder Ethylrest sein kann und R_2 nur ein Methylrest sein kann.

3. Verfahren nach Anspruch 2 zur Herstellung von 4-(Di-methylamino)-N-(2,6-dimethylphenyl)benzamid oder einem pharmazeutisch annehmbaren Salz davon.

4. Verfahren nach Anspruch 2 zur Herstellung von N-(2,6-Dimethylphenyl)-4-(methoxy)benzamid oder einem pharmazeutisch annehmbaren Salz davon.

5. Verfahren nach Anspruch 2 zur Herstellung von N-(2,6-Dimethylphenyl)-4-(cyano)benzamid oder einem pharmazeutisch annehmbaren Salz davon.

6. Verfahren zur Herstellung einer pharmazeutischen Zusammensetzung umfassend, daß man eine Verbindung der Formel (I):



(I)

worin R_1 ein Hydroxy-, C_1-C_4 -Alkoxy-, $-\text{S}(\text{O})_p-(\text{C}_1-\text{C}_4-\text{Alkyl})$ -, worin p 0 bis 2 ist, Trifluormethyl-, C_1-C_4 -Alkyl-, Aminomethyl-, Cyano-, primärer Amido-, 1-Imidazolylrest oder $-\text{NR}_3\text{R}_4$ ist, worin R_3 Wasserstoff oder ein C_1-C_3 -Alkylrest und R_4 ein C_1-C_3 -Alkylrest ist und R_2 ein Methyl-, Methoxy-, Trifluormethyl-, Hydroxymethyl- oder Chlorrest ist, oder ein pharmazeutisch annehmbares Salz davon mit einem oder mehreren pharmazeutisch annehmbaren Trägern oder Hilfsstoffen dafür vermischt.


7. Verfahren nach Anspruch 6 mit dem Vorbehalt, daß dann wenn R_3 Wasserstoff ist, R_4 nur ein Methyl- oder Ethylrest sein kann und R_2 nur ein Methylrest sein kann.

8. Verfahren nach Anspruch 7, worin die Verbindung der Formel (I) N-(2,6-Dimethylphenyl)-4-(methoxy)-benzamid oder ein pharmazeutisch annehmbares Salz davon ist.

Revendications

- 5 **Revendications pour les Etats contractants suivants : AT, BE, CH, DE, FR, GB, IT, LI, LU, NL, SE**

1. Composition pharmaceutique comprenant un composé de la formule (I)




20 dans laquelle R¹ représente un hydroxy, un alcoxy en C₁-C₄, un -S(O)_p-alkyle en C₁-C₄ dans lequel p est un nombre de 0 à 2, un trifluorométhyle, un alkyle en C₁-C₄, un aminométhyle, un cyano, un amide primaire, un imidazolyle -1- ou un -NR₃R₄, dans lequel R₃ représente de l'hydrogène ou un alkyle en C₁-C₃ et R₄ est un alkyle en C₁-C₃ et

R₂ est un méthyle, un méthoxy, un trifluorométhyle, un hydroxyméthyle ou un chloro, ou un sel pharmaceutiquement acceptable de ceux-ci associé à un ou plusieurs supports ou excipients pharmaceutiquement acceptables pour ceux-ci.

- 25 2. Composition pharmaceutique selon la revendication 1, dans laquelle si R₃ est de l'hydrogène, R₄ peut être uniquement un éthyle ou un méthyle et R₂ peut être uniquement un méthyle.

- 30 3. Composé selon la formule (I) tel que défini par la revendication 1 ou 2, ou un sel pharmaceutiquement acceptable de celui-ci à utiliser pour le traitement ou la prévention des convulsions chez les mammifères nécessitant ce traitement.

4. Composé de la formule (I)



45 dans laquelle R₁ est un -S(O)_p-alkyle en C₁-C₄ dans lequel p est un nombre de 0 à 2, un trifluorométhyle, un amide primaire, un cyano, un imidazole-1 ou -NR₃R₄ dans lequel R₃ représente de l'hydrogène ou un alkyle en C₁-C₃ et R₄ est un alkyle en C₁-C₃ et

R₂ est un méthyle, un méthoxy, un trifluorométhyle, un hydroxyméthyle ou un chloro, ou un sel pharmaceutiquement acceptable de ceux-ci.

5. Composé de la formule (I) selon la revendication 4, dans lequel si R₃ est de l'hydrogène, R₄ peut être uniquement un méthyle ou un éthyle et R₂ peut être uniquement un méthyle.


6. Composé de la formule (I) selon la revendication 5, dans lequel R₂ est un méthyle.

7. (Diméthylamino)--4-N-(diméthyl-2,6-phényl)-benzamide ou un sel pharmaceutiquement acceptable de celui-ci.


8. N-(diméthyl-2,6-phényl)-méthoxy-4-benzamide ou un sel pharmaceutiquement acceptable de celui-ci.

9. N-(diméthyl-2,6-phényl)-cyano-4-benzamide ou un sel pharmaceutiquement acceptable de celui-ci.


10. Procédé de préparation d'un composé de la formule (I) selon l'une quelconque des revendications 4 à 9 et qui comprend
a) l'acylation d'un composé de l'aniline de la formule (III)



par un composé de benzoyle de la formule (II)



dans laquelle R_1 et R_2 sont tels qu'indiqué pour la formule (I) de la revendication 1 et X est un bon groupe partant, afin d'obtenir un composé de la formule (I); ou
b) faire réagir un composé fluoré en 4 de la formule



avec une amine de la formule



ou un cycle 1H-imidazole dans lequel R_2 , R_3 et 4 ont les mêmes significations qu'à la formule (I) de la revendication 1 à des températures élevées afin d'obtenir un composé de la formule (I) dans lequel R_1 est un groupe de la formule $-NR_2R_3$ ou un cycle 1H-imidazole-1; ou
c) réduire un composé de la formule (I) de la revendication 1 dans lequel R_1 est un groupe cyano avec de l'hydrogène sur un catalyseur formé d'un métal de transition afin d'obtenir un composé de la formule (I) dans lequel R_1 est un groupe aminométhyle; ou
d) hydrolyser un composé de la formule (I) de la revendication 1 dans lequel R_2 est tel que défini pour la revendication 1 et dans lequel R_1 est un groupe cyano afin d'obtenir un composé de la revendication 1 dans lequel R_1 est un groupe amide primaire; ou
e) oxyder un composé de la formule (I) de la revendication 1 dans laquelle R_2 est tel que défini pour la revendication 1 et R_1 est un groupe de la formule




afin d'obtenir un composé de la revendication 1 dans lequel R_1 est un groupe de la formule



dans laquelle p représente 1 ou 2.

Revendications pour les Etats contractants suivants : ES, GR


1. Procédé de préparation d'un composé de formule (I)




dans laquelle R^1 représente un hydroxy, un alcoxy en C_1-C_4 , un $-Si(O)_p$ -alkyle en C_1-C_4 dans lequel p est un nombre de 0 à 2, un trifluorométhyle, un alkyle en C_1-C_4 , un aminométhyle, un cyano, un amide primaire, un imidazolyle -1- ou un $-NR_3R_4$, dans lequel R_2 représente de l'hydrogène ou un alkyle en C_1-C_3 et R_4 est un alkyle en C_1-C_3 et

R_2 est un méthyle, un méthoxy, un trifluorométhyle, un hydroxyméthyle ou un chloro, ou un sel pharmaceutiquement acceptable de ceux-ci ledit procédé comprenant les étapes suivantes :

a) l'acylation d'un composé de l'aniline de la formule (III)




par un composé de benzoyle de la formule (II)



dans laquelle R_1 et R_2 sont tels qu'indiqués pour la formule (I) de la revendication 1 et X est un bon groupe partant, afin d'obtenir un composé de la formule (I); ou

b) faire réagir un composé fluoré en 4 de la formule



avec une amine de la formule



ou un cycle 1H-imidazole dans lequel R_2 , R_3 , et R_4 ont les mêmes significations qu'à la formule (I) de la revendication 1 à des températures élevées afin d'obtenir un composé de la formule (I) dans lequel R_1 est un groupe de la formule $-NR_3R_4$ ou un cycle 1H-imidazole-1-; ou

c) réduire un composé de la formule (I) de la revendication 1 dans lequel R_1 est un groupe cyano avec de l'hydrogène sur un catalyseur formé d'un métal de transition afin d'obtenir un composé de

la formule (I) dans lequel R₁ est un groupe aminométhyle; ou
 d) hydrolyser un composé de la formule (I) de la revendication 1 dans lequel R₂ est tel que défini pour la revendication 1 et dans lequel R₁ est un groupe cyano afin d'obtenir un composé de la revendication 1 dans lequel R₁ est un groupe amide primaire; ou
 e) oxyder un composé de la formule (I) de la revendication 1 dans laquelle R₂ est tel que défini pour la revendication 1 et R₁ est un groupe de la formule




afin d'obtenir un composé de la revendication 1 dans lequel R₁ est un groupe de la formule



dans laquelle p représente 1 ou 2.

2. Procédé selon la revendication 1, à condition que si R₃ est de l'hydrogène, R₄ peut être uniquement un méthyle ou un éthyle et R₂ peut être uniquement un méthyle.
3. Procédé selon la revendication 2, pour préparer le (diméthylamino)-4-N-(diméthyl-2,6-phényl) benzamide ou un sel pharmaceutiquement acceptable de celui-ci.
4. Procédé selon la revendication 2, pour préparer le N-(diméthyl-2,6-phényl)-méthoxy-4-benzamide ou un sel pharmaceutiquement acceptable de celui-ci.
5. Procédé selon la revendication 2 pour préparer le N-(diméthyl-2,6-phényl)-cyano-4-benzamide ou un sel pharmaceutiquement acceptable de celui-ci.
6. Procédé de préparation d'une composition pharmaceutique comprenant le mélange d'un composé de la formule (I)



- dans laquelle R₁ représente un hydroxy, un alcoxy en C₁-C₄, un -S(O)_p-alkyle en C₁-C₄ dans lequel p est un nombre de 0 à 2, un trifluorométhyle, un alkyle en C₁-C₄, un aminométhyle, un cyano, un amide primaire; un 1-imidazole-1 ou un -NR₃R₄ dans lequel R₃ représente de l'hydrogène ou un alkyle en C₁-C₃, et R₄ est un alkyle en C₁-C₃ et
- R₂ est un méthyle, un méthoxy, un trifluorométhyle, un hydroxyméthyle ou un chloro, ou un sel pharmaceutiquement acceptable de ceux-ci associé à un ou plusieurs supports ou excipients pharmaceutiquement acceptables pour ceux-ci.
7. Procédé selon la revendication 6, dans lequel si R₃ est de l'hydrogène, R₄ peut être uniquement un méthyle ou un éthyle et R₂ peut être uniquement un méthyle.
 8. Procédé selon la revendication 7, dans lequel le composé de la formule (I) est le N-(diméthyl-2,6-phényl)-méthoxy-4-benzamide ou un sel pharmaceutiquement acceptable de celui-ci.